Emerging Antimicrobial Resistance

AMR Fundamentals - Resistance Rising

• Antimicrobial Resistance (AMR): Microbes evolve, making drugs ineffective.
• Global Crisis: ↑morbidity, ↑mortality, ↑costs. India: high AMR burden.
• Drivers: Antibiotic overuse (humans, animals), poor infection control (IPC).
• Impact: Treatment failure, prolonged illness, costly/toxic alternatives.

⭐ Key Definitions:

• MDR (Multidrug-Resistant): Non-susceptible to $\ge$1 agent in $\ge$3 antimicrobial categories.
• XDR (Extensively Drug-Resistant): Non-susceptible to $\ge$1 agent in all but $\le$2 categories.
• PDR (Pandrug-Resistant): Non-susceptible to all agents in all antimicrobial categories.

Resistance Mechanisms - Bugs' Clever Tricks

• Enzymatic Inactivation: Drug destroyed/modified.
  • $\beta$-lactamases: Hydrolyze $\beta$-lactam ring (Penicillinases, ESBLs, Carbapenemases like NDM-1, KPC).

  ⭐ Beta-lactamases, like penicillinase, break the $\beta$-lactam ring of antibiotics (e.g., penicillin), inactivating them.

  • Aminoglycoside-modifying enzymes (AMEs): Acetylation, phosphorylation.
  • Chloramphenicol Acetyltransferase (CAT).
• Target Site Modification: Drug binding site altered.
  • PBP change: mecA gene $\rightarrow$ PBP2a (MRSA).
  • Ribosome change: 23S rRNA methylation (erm genes) $\rightarrow$ Macrolide resistance.
  • Cell wall precursor: van genes (VRE) $\rightarrow$ D-Ala-D-Lac.
  • DNA gyrase/Topoisomerase IV mutation $\rightarrow$ Quinolone resistance.
• $\downarrow$ Permeability / Uptake: Drug entry blocked.
  • Porin loss/mutation (e.g., Gram-negatives vs carbapenems).
• Efflux Pumps: Drug actively expelled.
  • ATP-dependent pumps remove antibiotics (Tetracyclines, Macrolides).
  • Cause Multi-Drug Resistance (MDR). 📌 "Pump It Out!"

Key Resistant Pathogens - The Usual Suspects

• ESKAPE Pathogens (📌 Enterococcus, Staph, Klebsiella, Acinetobacter, Pseudomonas, Enterobacter): Major nosocomial threats & drivers of antimicrobial resistance.
  • MRSA (Staphylococcus aureus): Methicillin-resistant due to mecA gene (altered PBP2a).
  • VRE (Enterococcus faecium, E. faecalis): Vancomycin-resistant via vanA/vanB genes (altered D-Ala-D-Lac peptidoglycan target).
  • ESBL-producers (e.g., E. coli, Klebsiella pneumoniae): Extended-Spectrum β-Lactamases hydrolyze most penicillins, cephalosporins (1st-3rd gen), monobactams.
  • CRE (Carbapenem-Resistant Enterobacteriaceae e.g., Klebsiella, E. coli):
    • Key Carbapenemases: KPC, OXA-48 like, VIM, IMP.
  • MDR/XDR Acinetobacter baumannii: Multi-Drug Resistant / Extensively Drug-Resistant, often to carbapenems & colistin.
  • MDR/XDR Pseudomonas aeruginosa: Intrinsic & acquired resistance; difficult to treat.
• Indian Scenario Highlights:
  • High burden of NDM-1 (New Delhi Metallo-β-lactamase-1) producing Gram-negative bacteria.
  • Emergence of colistin resistance (e.g., plasmid-mediated mcr-1 gene).
  • Increasing resistance in Salmonella Typhi (fluoroquinolones, extended-spectrum cephalosporins).

⭐ NDM-1 (New Delhi metallo-beta-lactamase-1) is a prominent carbapenemase in India, conferring broad resistance to beta-lactams, including carbapenems, in Enterobacteriaceae and other Gram-negative bacteria.

Combating AMR - Our Strategic Moves

• Core Strategies (A.S.P.I.R.E. 📌):
  • Antimicrobial Stewardship (AMS): Optimize use (right drug, dose, duration).
  • Surveillance & Monitoring: Track resistance patterns (e.g., ICMR-AMRSN, NCDC).
  • Prevention & Control (IPC): Strengthen hand hygiene, sanitation, biosecurity.
  • Innovation (R&D): Develop new antibiotics, diagnostics, vaccines.
  • Regulation & Policy: Control OTC sales, ensure quality of antimicrobials.
  • Education & Awareness: For public, healthcare providers, policymakers.
• National Action Plan on AMR (NAP-AMR) India:
  • Launched 2017, based on WHO Global Action Plan.
  • Emphasizes 'One Health' across its strategic priorities.
  • ⭐ > The 'One Health' approach, integrating human, animal, and environmental health, is a cornerstone of India's National Action Plan on AMR.
• Global Collaboration: WHO GLASS, Global AMR R&D Hub.

High‑Yield Points - ⚡ Biggest Takeaways

• ESBLs, MBLs (e.g., NDM-1), KPC are major resistance mechanisms in Gram-negatives.
• MRSA (mecA) and VRE (vanA/vanB) remain critical Gram-positive resistant pathogens.
• Horizontal gene transfer via plasmids and transposons accelerates resistance spread.
• Biofilm formation significantly contributes to antibiotic treatment failure.
• MDR-TB and XDR-TB represent severe forms of drug-resistant tuberculosis.
• Emergence of colistin resistance (mcr-1 gene) limits last-resort treatment options.
• Antimicrobial stewardship programs are vital to control resistance.